Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson’s Disease
Miloš Stanojlović, Jean Pierre Pallais, Catherine M. Kotz
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 21

Showing 21 citing articles:

Biosensors in Parkinson’s disease
Ahmad Mobed, Siamak Razavi, Ali Ahmadalipour, et al.
Clinica Chimica Acta (2021) Vol. 518, pp. 51-58
Closed Access | Times Cited: 42
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies
Thuy Thi Lai, Birthe Gericke, Malte Feja, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 18
Orexin, serotonin, and energy balance
Vijayakumar Mavanji, Brianna Pomonis, Catherine M. Kotz
WIREs Mechanisms of Disease (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 36
Attention-deficit/hyperactivity disorder-related psychomotor activity and altered neuronal activity in the medial prefrontal cortex and striatum in the A53T mouse model of Parkinson's disease and other synucleinopathies: Findings from an “endophenotype” approach
Olga Dubljević, Željko Pavković, Maja Srbovan, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111273-111273
Closed Access
Multidimensional mechanisms of anxiety and depression in Parkinson’s Disease: integrating neuroimaging, neurocircuits, and molecular pathways
Jihu Zhao, Huafang Jia, Pengju Ma, et al.
Pharmacological Research (2025), pp. 107717-107717
Open Access
The role of orexin in Parkinson's disease
Alisha Braun, Jim Manavis, Akihiro Yamanaka, et al.
Journal of Neuroscience Research (2024) Vol. 102, Iss. 3
Open Access | Times Cited: 3
Interactions between Lateral Hypothalamic Orexin and Dorsal Raphe Circuitry in Energy Balance
Vijayakumar Mavanji, Brianna Pomonis, Laurie L. Shekels, et al.
Brain Sciences (2024) Vol. 14, Iss. 5, pp. 464-464
Open Access | Times Cited: 3
Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential
Cui Liu, Yan Xue, Meifang Liu, et al.
Neurochemistry International (2020) Vol. 138, pp. 104754-104754
Closed Access | Times Cited: 25
Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease
Eileen Ruth S. Torres, Miloš Stanojlović, Moriel Zelikowsky, et al.
Neurobiology of Disease (2021) Vol. 158, pp. 105478-105478
Open Access | Times Cited: 22
Several neuropeptides involved in parkinsonian neuroprotection modulate the firing properties of nigral dopaminergic neurons
Lei Chen, Cui Liu, Yan Xue, et al.
Neuropeptides (2023) Vol. 99, pp. 102337-102337
Closed Access | Times Cited: 8
Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
Fionya H. Tran, Stella L. Spears, Kyung Jin Ahn, et al.
Neuroscience Letters (2020) Vol. 739, pp. 135432-135432
Open Access | Times Cited: 22
Sex-dimorphic functions of orexin in neuropsychiatric disorders
Jinghan Zhang, Kangyu Jin, Bing Chen, et al.
Heliyon (2024) Vol. 10, Iss. 16, pp. e36402-e36402
Open Access | Times Cited: 2
Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson’s Disease
Miloš Stanojlović, Jean Pierre Pallais, Catherine M. Kotz
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 795-795
Open Access | Times Cited: 14
Content of Peripheral Blood T- and B-Cell Subpopulations in Transgenic A53T Mice of Different Age (A Model of Parkinson’s Disease)
Г. В. Идова, Е. Л. Альперина, M. M. Gevorgyan, et al.
Bulletin of Experimental Biology and Medicine (2021) Vol. 170, Iss. 4, pp. 401-404
Closed Access | Times Cited: 10
Parkinson disease: Protective role and function of neuropeptides
Mireille Tabikh, Charbel Chahla, Nathalie Okdeh, et al.
Peptides (2021) Vol. 151, pp. 170713-170713
Open Access | Times Cited: 9
Orexin-A in Patients With Lewy Body Disease: A Systematic Review and Meta-Analysis
Jinghuan Gan, Zhichao Chen, Jiuyan Han, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 7
Orexin enhances neuronal synchronization in adult rat hypothalamic culture: a model to study hypothalamic function
Vijayakumar Mavanji, Apostolos P. Georgopoulos, Catherine M. Kotz
Journal of Neurophysiology (2022) Vol. 127, Iss. 5, pp. 1221-1229
Open Access | Times Cited: 4
Effects of Lanthionine Ketimine-5-Ethyl Ester on the α-Synucleinopathy Mouse Model
Arina Yazawa, Kenneth Hensley, Toshio Ohshima
Neurochemical Research (2022) Vol. 47, Iss. 8, pp. 2373-2382
Closed Access | Times Cited: 3
A Bitter Experience That Enlightens the Future: COVID-19 Neurological Affection and Perspectives on the Orexigenic System
Sherine Abdelmissih
Cureus (2022)
Open Access | Times Cited: 1
Research Progress on the Effect of Orexin During Peri-Anaesthesia
秀秀 赵
Advances in Clinical Medicine (2020) Vol. 10, Iss. 03, pp. 354-359
Closed Access
Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
Fionya H. Tran, Stella L. Spears, Kyung Jin Ahn, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access
Page 1

Scroll to top